Would you pay $475,000 for a 30 percent chance of forcing an aggressive cancer into remission? Questions like these continue to propagate. Innovative and effective cell therapy treatments are advancing in the R&D pipeline with some major first in class approvals last year, but costs and logistical challenges have been limiting the commercial success of the…